All Stories

  1. An Updated Meta-Analysis of Randomized Controlled Trials Comparing Direct Oral Anticoagulants Against Warfarin for Left Ventricular Thrombus Resolution
  2. Response by Bulluck and Hausenloy to Letter Regarding Article, “Effect of Cangrelor on Infarct Size in ST-Segment–Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (the PITRI Trial)”
  3. Letter to the Editor Regarding “A Meta-Analysis of RCTs Comparing DOACs Against Warfarin for the Treatment of Left Ventricular Thrombus”
  4. Effect of Cangrelor on Infarct Size in ST-Segment–Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial)
  5. Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention on Medium-Term Outcomes: A Contemporary Meta-Analysis of Randomized Controlled Trials
  6. A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice
  7. Defining Peri-Operative Myocardial Injury during Cardiac Surgery Using High-Sensitivity Troponin T
  8. Meta-Analysis Comparing Clinical Outcomes of Fractional-Flow-Reserve- and Angiography-Guided Multivessel Percutaneous Coronary Intervention
  9. Fractional Flow Reserve versus Angiography–Guided Management of Coronary Artery Disease: A Meta–Analysis of Contemporary Randomised Controlled Trials
  10. Meta-Analysis Comparing 10-Year Mortality Following Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in Left Main Stem or Multivessel Coronary Artery Disease
  11. Incidence and Clinical Predictors of Non-Obstructive Coronary Arteries in Patients With Suspected Non-ST Elevation Myocardial Infarction Undergoing Invasive Coronary Angiography
  12. Contemporary tools and devices for coronary calcium modification
  13. Prognostically relevant cardiac troponin elevations with percutaneous coronary interventions
  14. Combining Invasive Coronary Physiology With CMR for Long-Term Risk-Stratification in STEMI
  15. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiov...
  16. Association between smoking status and outcomes in myocardial infarction patients undergoing percutaneous coronary intervention
  17. T and Small Protrusion (TAP) vs Double-Kissing Crush Technique: Insights From In Vitro Models
  18. Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data
  19. Response to the letter to the editor regarding the study “Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality” published in the American Heart Journal
  20. Effect of remote ischemic preConditioning on liver injury in patients undergoing liver resection: the ERIC-LIVER trial
  21. Cardioprotection for Acute MI in Light of the CONDI2/ERIC-PPCI Trial: New Targets Needed
  22. Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segment–Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis
  23. The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry
  24. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease
  25. Periprocedural elevated myocardial biomarkers and clinical outcomes following elective percutaneous coronary intervention: a comprehensive dose-response meta-analysis of 44,972 patients from 24 prospective studies
  26. Periprocedural Cardiac Troponin and Mortality in Stable Patients Undergoing PCI
  27. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial
  28. A Multicenter, Scan-Rescan, Human and Machine Learning CMR Study to Test Generalizability and Precision in Imaging Biomarker Analysis
  29. The Effect of Blood Composition on T1 Mapping
  30. Toward Improving Our Understanding of the Relationship Between IMR and MVO in STEMI Patients
  31. Independent Predictors of Cardiac Mortality and Hospitalization for Heart Failure in a Multi-Ethnic Asian ST-segment Elevation Myocardial Infarction Population Treated by Primary Percutaneous Coronary Intervention
  32. Optimized Treatment of ST-Elevation Myocardial Infarction
  33. Interrogation of the infarcted and salvaged myocardium using multi-parametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients
  34. Feasibility to Perform T 2 * Mapping Postcontrast Administration in Reperfused STEMI Patients for the Detection of Intramyocardial Hemorrhage
  35. Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial
  36. Defining a ‘frequent admitter’ phenotype among patients with repeat heart failure admissions
  37. Platelet Inhibition to Target Reperfusion Injury (The PITRI trial): Rationale and Study Design
  38. Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis
  39. Coronary Microvascular Injury in Reperfused Acute Myocardial Infarction: A View From an Integrative Perspective
  40. Optimizing the Detection of Left Ventricular Thrombus Following Acute Myocardial Infarction in the Current Era
  41. Modulating NAD+ metabolism to prevent acute kidney injury
  42. Risk Stratification by Cardiovascular Magnetic Resonance After Reperfused ST-Segment Elevation Myocardial Infarction
  43. Impact of Cardioprotective Therapies on the Edema-Based Area at Risk by CMR in Reperfused STEMI
  44. Myocardial Edema and Prognosis in Amyloidosis
  45. Percutaneous coronary intervention of saphenous vein grafts: where do we stand?
  46. Cardiovascular Magnetic Resonance in Acute ST-Segment–Elevation Myocardial Infarction
  47. Letter by Bulluck and Hausenloy Regarding Article, “Dynamic Edematous Response of the Human Heart to Myocardial Infarction: Implications for Assessing Myocardial Area at Risk and Salvage”
  48. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles
  49. Myocardial native T1 and extracellular volume with healthy ageing and gender
  50. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
  51. Fundamentals of bioresorbable stents
  52. Bioresorbable Scaffold Stability and Mechanical Properties
  53. Left Ventricular Hypertrophy Revisited
  54. Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes
  55. Redefining viability by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction
  56. Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
  57. Response by Andrews et al to Letter Regarding Article, “Electrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imaging”
  58. Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality
  59. Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping
  60. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery
  61. Full left ventricular coverage is essential for the accurate quantification of the area-at-risk by T1 and T2 mapping
  62. Mapping Myocardial Salvage Index by Extracellular Volume Fraction
  63. Electrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imaging
  64. Magnetic Resonance in Transthyretin Cardiac Amyloidosis
  65. Quantifying the area-at-risk of myocardial infarction in-vivo using arterial spin labeling cardiac magnetic resonance
  66. Reply to “Circadian variation in acute myocardial infarction size: Likely involvement of the melatonin and suprachiasmatic nuclei”
  67. 024 Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis
  68. 001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis
  69. Age and Surgical Complexity impact on Renoprotection by Remote Ischemic Preconditioning during Adult Cardiac Surgery: A Meta analysis
  70. Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance
  71. Circadian variation in acute myocardial infarct size assessed by cardiovascular magnetic resonance in reperfused STEMI patients
  72. Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies
  73. Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment–Elevation Myocardial Infarction Patients
  74. Diagnostic performance of T 1 and T 2 mapping to detect intramyocardial hemorrhage in reperfused ST-segment elevation myocardial infarction (STEMI) patients
  75. Reply
  76. Bioresorbable stents: Current and upcoming bioresorbable technologies
  77. Gender Differences in Native Myocardial T1 in a Healthy Chinese Volunteer Cohort
  78. Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance
  79. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy
  80. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”
  81. Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment–Elevation Myocardial Infarction and Adverse Left Ventricular RemodelingCLINICAL PERSPECTIVE
  82. Index of Microvascular Resistance and Microvascular Obstruction in Patients With Acute Myocardial Infarction
  83. Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy
  84. Optimization of coronary optical coherence tomography imaging using the attenuation-compensated technique: a validation study
  85. Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post–Reperfused ST‐Elevation Myocardial Infarction
  86. ORAL AB II QUICK FIRE BASIC1393Validation of aortic in-vitro strain measurement by Magnetic Resonance Imaging with realistic abdominal aortic aneurism phantom1474A novel method of Segment Length Tracking providing regional strain measures from standard...
  87. Response to Letters Regarding Article, “Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis”
  88. Quantifying the Area at Risk in Reperfused ST-Segment–Elevation Myocardial Infarction Patients Using Hybrid Cardiac Positron Emission Tomography–Magnetic Resonance ImagingCLINICAL PERSPECTIVE
  89. Global longitudinal strain is associated with heart failure outcomes in hypertrophic cardiomyopathy
  90. Letter by Bulluck and Hausenloy Regarding Article, “Air Versus Oxygen in ST-Segment–Elevation Myocardial Infarction”
  91. High-sensitivity Troponin-T levels in reperfused STEMI patients: A comparison with CMR
  92. Chronic iron deposit and left ventricular remodeling in reperfused STEMI patients
  93. Left ventricular remodeling after reperfused acute myocardial infarction: insights from automated ECV mapping
  94. Automatic Measurement of the Myocardial Interstitium
  95. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials
  96. Remote Ischemic Preconditioning: Would You Give Your Right Arm to Protect Your Kidneys?
  97. CMR findings in high endurance veteran athletes - a 247 subject study
  98. Diffuse myocardial fibrosis - a therapeutic target? Proof of regression at 1-year following aortic valve replacement: the RELIEF-AS study
  99. ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
  100. Hematocrit, iron and HDL-cholesterol explain 90% of variation in native blood T1
  101. Native myocardial T1 and ECV with age and gender developing normal reference ranges - a 94 healthy volunteer study
  102. Reproducibility of native T1 mapping using ShMOLLI and MOLLI - implications for sample size calculation
  103. The Right ventricle and cardiac surgery - more resilient than thought: multiparametric quantification shows altered rather than reduced function
  104. Reducing myocardial infarct size: challenges and future opportunities
  105. Microvascular Obstruction: The Bane of Myocardial Reperfusion
  106. Obstrucción microvascular: el azote de la reperfusión miocárdica
  107. The Effect of Remote Ischemic Conditioning and Glyceryl Trinitrate on Perioperative Myocardial Injury in Cardiac Bypass Surgery Patients: Rationale and Design of the ERIC-GTN Study
  108. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac AmyloidosisCLINICAL PERSPECTIVE
  109. T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients
  110. CardioPulse ArticlesEditors' network of the European Society of Cardiology National Cardiovascular Journals: scientific input from the National SocietiesHand grip strength predicts myocardial infarction and strokeEffect of remote ischaemic conditioning...
  111. Remote Ischemic Conditioning Reduces Myocardial Infarct Size in STEMI Patients Treated by Thrombolysis
  112. Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design
  113. Ischaemic conditioning: are we there yet?
  114. 29 Synthetic ECV – simplifying ECV quantification by deriving haematocrit from T1 blood
  115. Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials
  116. An instantaneous ECV with no blood sampling: using native blood T1 for hematocrit is as good as standard ECV
  117. Clinical application of MOLLI T1* for extracellular volume calculation in healthy volunteers and aortic stenosis
  118. Hybrid PET/MR metabolic imaging of the reperfused infarct - new biology, future directions
  119. Incidence of left ventricular thrombi in reperfused STEMI patients detected by contrast-enhanced CMR
  120. LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study
  121. Myocardial T1 Mapping
  122. Myocardial iron quantification using T2* and native T1mapping - a 250 patient study
  123. Performance of automated ECV maps versus conventionally calculated ECV
  124. Precision and reproducibility of blood T1 estimation: implications of T1 star on ECV calculation
  125. Quantification of the area-at-risk by T1 and T2 mapping CMR at 3T
  126. A simple technique to measure TAPSE and MAPSE on CMR and normal values
  127. AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology
  128. Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
  129. CMR detects a reduction in infarct size and myocardial edema when primary PCI is augmented by Remote Ischemic Conditioning. A randomized trial
  130. 045 PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST ELEVATION MYOCARDIAL INFARCTION: DOES DIRECT STENTING IMPACT ON MORTALITY?
  131. The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk)
  132. S1238 Serum Lipids and the Risk of Developing Symptomatic Gallstones: A UK Prospective Cohort Study
  133. OC-030 Serum lipids and the risk of developing symptomatic gallstones: a UK prospective cohort study
  134. 14 Body Mass Index and the Risk of Symptomatic Gallstones - A Prospective Cohort Study in a UK Population
  135. 15 Alcohol Intake and Development of Symptomatic Gallstones: An Inverse Association - A UK Prospective Cohort Study